Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
BAL2420 offers a novel mode of action to address serious Gram‑negative bacterial infections, which remain of particular concern because of…
BEAM at work
Our advocacy work is based on analysis and reflection with our members.
Each topic is dealt with by a task force, which acts as a discussion platform and issues policy briefs.
